SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
BURLINGTON, Mass., March 28, 2017 -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Michael Clayman, M.D., President and Chief Executive Officer, will present at Needham & Company’s 16th Annual Healthcare Conference on Tuesday, April 4, 2017 at 3:40 p.m. EDT at the Westin Grand Central Hotel in New York.
To access the live webcast and subsequent archived recordings for the presentation, please visit the Flexion website at http://flexiontherapeutics.com/.
About Flexion Therapeutics
Flexion is a specialty pharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA). The company's lead product candidate, Zilretta™ (FX006), is being investigated for its potential to provide improved analgesia for the millions of U.S. patients who receive intra-articular injections for OA related knee pain annually.
Corporate Contact: Scott Young Sr. Director, Corporate Communications & Investor Relations Flexion Therapeutics, Inc. T: 781-305-7194 [email protected]
